496 related articles for article (PubMed ID: 16154839)
21. Prognostic value of trisomy 8 in primary myelodysplastic syndrome.
Ma Y; Wang X; Xu X; Lin G
Intern Med J; 2010 Oct; 40(10):697-703. PubMed ID: 19811560
[TBL] [Abstract][Full Text] [Related]
22. Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes.
Wang J; Ai X; Qin T; Xu Z; Zhang Y; Liu J; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Cai W; Ru K; Jia Y; Huang G; Xiao Z
Oncotarget; 2017 Jan; 8(1):1603-1612. PubMed ID: 27906673
[TBL] [Abstract][Full Text] [Related]
23. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies.
Huang TC; Ko BS; Tang JL; Hsu C; Chen CY; Tsay W; Huang SY; Yao M; Chen YC; Shen MC; Wang CH; Tien HF
Leukemia; 2008 Mar; 22(3):544-50. PubMed ID: 18094713
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes.
Jotterand M; Parlier V
Leuk Lymphoma; 1996 Oct; 23(3-4):253-66. PubMed ID: 9031106
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan.
Toyama K; Ohyashiki K; Yoshida Y; Abe T; Asano S; Hirai H; Hirashima K; Hotta T; Kuramoto A; Kuriya S
Leukemia; 1993 Apr; 7(4):499-508. PubMed ID: 8464227
[TBL] [Abstract][Full Text] [Related]
26. [Cytogenetic profile in patients with primary myelodysplastic syndrome].
Gritsaev SV; Martynkevich IS; Petrova EV; Martynenko LS; Ivanova MP; Aksenova VIu; Tsybakova NIu; Potikhonova NA; Abdulkadyrov KM
Ter Arkh; 2013; 85(7):43-9. PubMed ID: 24137946
[TBL] [Abstract][Full Text] [Related]
27. Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome.
Sánchez-Castro J; Marco-Betés V; Gómez-Arbonés X; Arenillas L; Valcarcel D; Vallespí T; Costa D; Nomdedeu B; Jimenez MJ; Granada I; Grau J; Ardanaz MT; de la Serna J; Carbonell F; Cervera J; Sierra A; Luño E; Cervero CJ; Falantes J; Calasanz MJ; González-Porrás JR; Bailén A; Amigo ML; Sanz G; Solé F
Leuk Res; 2013 Jul; 37(7):769-76. PubMed ID: 23639672
[TBL] [Abstract][Full Text] [Related]
28. Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome.
Wang H; Wang XQ; Xu XP; Lin GW
Cancer Genet Cytogenet; 2010 Jan; 196(2):159-66. PubMed ID: 20082852
[TBL] [Abstract][Full Text] [Related]
29. Chromosomal abnormalities in primary myelodysplastic syndrome.
Rashid A; Khurshid M; Shaikh U; Adil S
J Coll Physicians Surg Pak; 2014 Sep; 24(9):632-5. PubMed ID: 25233965
[TBL] [Abstract][Full Text] [Related]
30. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.
Bacher U; Haferlach T; Schnittger S; Zenger M; Meggendorfer M; Jeromin S; Roller A; Grossmann V; Krauth MT; Alpermann T; Kern W; Haferlach C
Br J Haematol; 2014 Mar; 164(6):822-33. PubMed ID: 24372512
[TBL] [Abstract][Full Text] [Related]
31. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.
Schanz J; Tüchler H; Solé F; Mallo M; Luño E; Cervera J; Granada I; Hildebrandt B; Slovak ML; Ohyashiki K; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Valent P; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Garcia-Manero G; Faderl S; Pierce S; Le Beau MM; Bennett JM; Greenberg P; Germing U; Haase D
J Clin Oncol; 2012 Mar; 30(8):820-9. PubMed ID: 22331955
[TBL] [Abstract][Full Text] [Related]
32. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
Sébert M; Komrokji RS; Sekeres MA; Prebet T; Cluzeau T; Santini V; Gyan E; Sanna A; Ali NH; Hobson S; Eclache V; List A; Fenaux P; Adès L
Leuk Res; 2017 Dec; 63():72-77. PubMed ID: 29112938
[TBL] [Abstract][Full Text] [Related]
33. [WHO classification and cytogenetic analysis of 435 cases with myelodysplastic syndrome].
Wang XQ;
Zhonghua Nei Ke Za Zhi; 2008 Jun; 47(6):464-7. PubMed ID: 19040061
[TBL] [Abstract][Full Text] [Related]
34. External validation of newly proposed cytogenetic risk classification in patients who have myelodysplastic syndrome: a retrospective analysis at a single institution.
Yun J; Kim DH; Kong JH; Kim HJ; Kim SH; Kim K; Jang JH; Jung CW
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):273-9. PubMed ID: 21658655
[TBL] [Abstract][Full Text] [Related]
35. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
[TBL] [Abstract][Full Text] [Related]
36. Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center study.
Qu S; Xu Z; Zhang Y; Qin T; Zhang T; Cui R; Xiao Z
Leuk Lymphoma; 2012 May; 53(5):940-6. PubMed ID: 22023524
[TBL] [Abstract][Full Text] [Related]
37. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
38. [The clinical features, cytogenetic characteristics and survival analysis of 550 myelodysplastic syndromes in a single center].
Zhang TT; Sun AN; Pan JL; Wu DP; Qiu HY; Tang XW; Miao M; Chen SN
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):864-869. PubMed ID: 27801317
[TBL] [Abstract][Full Text] [Related]
39. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
Germing U; Hildebrandt B; Pfeilstöcker M; Nösslinger T; Valent P; Fonatsch C; Lübbert M; Haase D; Steidl C; Krieger O; Stauder R; Giagounidis AA; Strupp C; Kündgen A; Mueller T; Haas R; Gattermann N; Aul C
Leukemia; 2005 Dec; 19(12):2223-31. PubMed ID: 16193087
[TBL] [Abstract][Full Text] [Related]
40. [Cytogenetics of myelodysplastic syndromes and its impact as prognostic factor].
Borjas-Gutiérrez C; Domínguez-Cruz MD; González-García JR
Rev Med Inst Mex Seguro Soc; 2017; 55(4):481-489. PubMed ID: 28591503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
